Association of Childhood Growth Hormone Treatment With Long-term Cardiovascular Morbidity

Authors:

Abstract
Treatment with recombinant human growth hormone (rhGH) has been in clinical use since 1985, with treatment indications now extending beyond growth hormone deficiency (GHD) to include an increasing number of conditions in which childhood short stature is not primarily due to deficient endogenous growth hormone secretion, such as small for gestational age (SGA) without catch-up growth or idiopathic short stature (ISS).1 Apart from regulating linear growth during childhood, growth hormone and its prime mediator, insulinlike growth factor 1, have several effects on the metabolism of fat, protein, and carbohydrates2 as well as on the cardiovascular system.3,4 Moreover, both excess levels of growth hormone and GHD have been associated with increased cardiovascular morbidity and mortality.5-7

This publication has 42 references indexed in Scilit: